Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Samsung Looks To Mirror Fellow Korean Pharma Celltrion's Path From CMO To Biosimilars Developer With Quintiles JV

This article was originally published in The Pink Sheet Daily

Executive Summary

Samsung plans to begin construction on its manufacturing plant in Incheon during the first half of this year, and production is expected to commence in the first half of 2013.
Advertisement

Related Content

And Now For The Real Biosimilar Opportunity: Antibodies And Complex Biologics
And Now For The Real Biosimilar Opportunity: Antibodies And Complex Biologics
Change Of Guard At Quintiles India As Company Continues Aggressive Asia Efforts With Samsung Deal
Biosimilars Aid Korea's Celltrion To Post Record Sales And Profit In FY 2010
Takeda Goes Virtual, Splitting Non-oncology Development Between Covance And Quintiles
Samsung Electronics Takes Step Into Korea's Biosimilar Foray With IND For MabThera Generic
Samsung Electronics Takes Over Leading Medical Device Maker Medison
Samsung Group Set To Enter Biosimilars Market With $1.9 Billion Investment
Korea's Samsung Electronics On Manhunt For Biosimilar Talent As Local Companies Keep Wary Eye On Competition

Topics

Advertisement
UsernamePublicRestriction

Register

PS071930

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel